The side effect burden associated with drug treatment of panic disorder

Journal of Clinical Psychiatry

Volumn 59, Issue SUPPL.8, 1998, Pages 39-46

  Baldwin, David S ^a   Birtwistle, Jon ^a  

^a ROYAL SOUTH HANTS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; CITALOPRAM; CLONAZEPAM; DIAZEPAM; FLUVOXAMINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

CONSTIPATION; DIARRHEA; DRUG INDUCED DISEASE; DRUG RESEARCH; DRUG TOLERABILITY; HEADACHE; HUMAN; IMPOTENCE; MEDICAL INFORMATION; PANIC; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; TREMOR; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BENZODIAZEPINES; CITALOPRAM; CLONAZEPAM; HUMANS; PANIC DISORDER; PAROXETINE; SEROTONIN UPTAKE INHIBITORS;

EID: 0031903823     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ 1995;310:1433-1438
2. Steffens DC, Krishnan KR, Helms MJ. Are SSRIs better than TCAs? comparison of SSRIs and TCAs: a meta-analysis. Depress Anxiety 1997;6: 10-18
3. Martin RM, Hilton SR, Kerry SM, et al. General practitioners perceptions of the tolerability of antidepressant drugs: a comparison of selective serotonin reuptake inhibitors and tricyclic antidepressants. BMJ 1997;314: 646-651
4. Pohl R, Yerangani VK, Balson R, et al. The jitteriness syndrome in panic disorder patients treated with antidepressants. J Clin Psychiatry 1988;49: 100-104
5. Modigh K, Westberg P, Eirksson E. Superiority of clomipramme over imipramine in the treatment of panic disorder: a placebo-controlled trial. J Clin Psychopharmacol 1992;12:251-261
6. Fahy TJ, O'Rourke D, Brophy J, et al. The Galway Study of Panic Disorder, I: clomipramine and lofepramine in DSM-III-R panic disorder: a placebo-controlled trial. J Affect Disord 1992;25:63-76
7. Black DW, Wesner R, Bowers W, et al. A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry 1993;50:44-50
8. de Beurs E, van Balkom AJLM, Lange A, et al. Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone. Am J Psychiatry 1995;152:683-691
9. den Boer JA, Westenberg HGM. Serotonin function in panic disorder: a double-blind placebo-controlled study with fluvoxamine and ritanserin. Psychopharmacology (Berl) 1990;102:85-94
10. Bakish D, Hooper CL, Fiteau MJ, et al. A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia. Psychopharmacol Bull 1996;32: 135-141
11. Oehrberg S, Christiansen PE, Behnke K, et al. Paroxetine in the treatment of panic disorder: a randomised, double-blind, placebo-controlled study. Br J Psychiatry 1995;167:374-379
12. Lecrubier Y, Bakker A, Dunbar G, et al. A comparison of paroxetine, clomipramine, and placebo in the treatment of panic disorder. Acta Psychiatr Scand 1997;95:145-152
13. Lecrubier Y, Judge R, and the Collaborative Paroxetine Panic Study Investigators. Long-term evaluation of paroxetine, clomipramine, and placebo in panic disorder. Acta Psychiatr Scand 1997;95:153-160
14. Wade AG, Lepola U, Koponen HJ, et al. The effect of citalopram in panic disorder. Br J Psychiatry 1997;170:549-553
15. Pecknold JC, Swinson RP, Kuch K, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. III: discontinuation effects. Arch Gen Psychiatry 1988;45:429-436
16. Noyes RN, Clancey J, Coryell WH, et al. A withdrawal syndrome after abrupt discontinuation of alprazolam. Am J Psychiatry 1985;142:114-116
17. Klein E, Colin V, Stolk J, et al. Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazepine. Am J Psychiatry 1994;151:1760-1766
18. Lydiard RB, Lesser IM, Ballenger JC, et al. A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder. J Clin Psychopharmacol 1992;12:96-103
19. Pecknold J, Luthe L, Munjack D, et al. A double-blind, placebo-controlled, multicentre study with alprazolam and extended-release alprazolam in the treatment of panic disorder. J Clin Psychopharmacol 1994;14:314-321
20. Schweizer E, Patterson W, Rickels K, et al. Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder. Am J Psychiatry 1993;150: 1210-1215
21. Noyes R Jr, DuPont RL, Pecknold JC, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. Arch Gen Psychiatry 1988;45:423-428
22. Cross-National Collaborative Panic Study, Second Phase Investigators. Drug treatment of panic disorder: comparative efficacy of alprazolam, imipramine, and placebo. Br J Psychiatry 1992;160:191-202
23. Beauclair L, Fontaine R, Annable L, et al. Clonazepam in the treatment of panic disorder: a double-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response. J Clin Psychopharmacol 1994;14:111-118
24. Noyes R Jr, Burrows GD, Reich JH, et al. Diazepam versus alprazolam tor the treatment of panic disorder. J Clin Psychiatry 1996;57:349-355
25. Baldwin DS, Thomas SC, Birtwistle J. Effects of antidepressant drugs on sexual function. Int J Psychiatry Clin Pract 1997;1:47-58
26. Montejo-Gonzalez AL, Llorca G, Izquierdo JA, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicentre, and descriptive clinical study of 344 patients. J Sex Marital Ther 1997;23:176-194